Gould R J, Murphy K M, Snyder S H
Life Sci. 1983 Dec 26;33(26):2665-72. doi: 10.1016/0024-3205(83)90351-x.
A radioreceptor assay for calcium channel antagonist drugs described here is based on the ability of these drugs to affect 3H-nitrendipine binding to calcium channels. All the known calcium channel antagonists may be assayed in this manner. The assay can detect 10-100 nM (4 - 40 ng/ml) nimodipine, 10-100 nM (3.5 - 35 ng/ml) nifedipine, 3-30 microM (1.2 - 12 micrograms/ml) prenylamine, 0.1 - 1.0 microM (49 - 490 ng/ml) verapamil and 3-30 microM (1.2 - 12 micrograms/ml) diltiazem. These values cover the range of concentrations of calcium channel antagonists that are clinically important. As the radioreceptor assay detects active metabolites as well as the parent drugs, it should prove a useful adjunct in cardiovascular therapy. The method is more reproducible, simpler and less expensive than other methods such as high pressure liquid chromatography.
本文所述的钙通道拮抗剂药物放射受体测定法是基于这些药物影响³H-尼莫地平与钙通道结合的能力。所有已知的钙通道拮抗剂都可以用这种方式进行测定。该测定法能够检测出10 - 100 nM(4 - 40 ng/ml)的尼莫地平、10 - 100 nM(3.5 - 35 ng/ml)的硝苯地平、3 - 30 μM(1.2 - 12 μg/ml)的普尼拉明、0.1 - 1.0 μM(49 - 490 ng/ml)的维拉帕米以及3 - 30 μM(1.2 - 12 μg/ml)的地尔硫䓬。这些数值涵盖了临床上重要的钙通道拮抗剂浓度范围。由于放射受体测定法既能检测活性代谢物又能检测母体药物,因此它应可证明是心血管治疗中的一种有用辅助手段。该方法比诸如高压液相色谱等其他方法更具可重复性、更简单且成本更低。